-
Demographic, clinical, and sociocognitive determinants related to physical activity and dietary intake in patients with ovarian cancer: A cross-sectional study Gynecol. Oncol. (IF 4.7) Pub Date : 2024-03-18 Yvonne A.W. Hartman, Marlou-Floor Kenkhuis, Stephanie Stelten, Calvin G. Brouwer, Luc R.C.W. van Lonkhuijzen, Gemma G. Kenter, Willemien J. van Driel, Renate M. Winkels, Ruud L.M. Bekkers, Nelleke P.B. Ottevanger, Meeke Hoedjes, Laurien M. Buffart
To study physical activity and dietary intake among patients with ovarian cancer and to examine which demographic, clinical, and sociocognitive determinants are associated with these behaviours. This cross-sectional study included 139 patients with ovarian cancer scheduled for (neo)adjuvant chemotherapy. Physical activity was measured with the Physical Activity Scale for the Elderly questionnaire (PASE)
-
Letter re: Ban et al., A personalized probabilistic approach to ovarian cancer diagnostics Gynecol. Oncol. (IF 4.7) Pub Date : 2024-03-16 Beverly J. Levine
-
Mainstreaming in parallel with ovarian cancer tumor testing to improve genetic testing uptake Gynecol. Oncol. (IF 4.7) Pub Date : 2024-03-15 Maureen Byrne, Tiffany Y. Sia, Christopher Fong, Aliya Khurram, Michele Waters, Yelena M. Kemel, Qin Zhou, Megha Ranganathan, Kara Long Roche, Dennis S. Chi, Sally Saban, Michelle Wu, Nancy Varice, Jada G. Hamilton, Jian Carrot-Zhang, Nadeem R. Abu-Rustum, Alexia Iasonos, Lora H. Ellenson, Diana Mandelker, Britta Weigelt, Carol L. Brown, Carol Aghajanian, Zsofia Stadler, Ying L. Liu
Although genetic testing (GT) is universally recommended for patients with epithelial ovarian cancer (EOC), rates are low (34%). In 1/2019, we implemented mainstreaming—GT in parallel with tumor testing via MSK-IMPACT within oncology clinics. We sought to determine GT rates pre/post-mainstreaming and patient characteristics associated with GT. Patients with newly diagnosed EOC seen at our institution
-
Fertility potential and safety assessment of residual ovarian cortex in young women diagnosed with epithelial borderline and early-stage malignant ovarian tumors Gynecol. Oncol. (IF 4.7) Pub Date : 2024-03-15 L. Cacciottola, A. Camboni, E. Gatti, E. Marbaix, M. Vignali, J. Donnez, M.M. Dolmans
To establish the safety and quality of ovarian cortex surrounding epithelial ovarian tumors in women eligible for fertility-sparing surgery by identifying occult malignant lesions and characterizing the ovarian follicle pool. Multicentric retrospective study of 48 subjects (15–45 years), diagnosed with borderline ovarian tumors (BOTs) or early-stage epithelial ovarian cancers (EOCs) and eligible for
-
Evaluating outcomes and toxicities for a newly implemented MRI-based brachytherapy program for cervical cancer Gynecol. Oncol. (IF 4.7) Pub Date : 2024-03-15 Dylan H. Ross, Kayeromi Gomez, Grant Harmon, Michael L. Mysz, Steven M. Shea, Ari Goldberg, Margaret Liotta, Ronald Potkul, Abigail Winder, Brian Lee, Jacob Jackson, John C. Roeske, William Small Jr, Matthew M. Harkenrider
We report an updated analysis of the outcomes and toxicities of MRI-based brachytherapy for locally advanced cervical cancer from a U.S. academic center. A retrospective review was performed on patients treated with MRI-based brachytherapy for cervical cancer. EBRT was standardly 45 Gy in 25 fractions with weekly cisplatin. MRI was performed with the brachytherapy applicator in situ. Dose specification
-
Primary results of the AGO-Zervix-1 Study: A prospective, randomized phase III study to compare the effects of paclitaxel and topotecan with those of cisplatin and topotecan in the treatment of patients with recurrent and persistent cervical cancer Gynecol. Oncol. (IF 4.7) Pub Date : 2024-03-14 Paul Gass, Falk C. Thiel, Lothar Häberle, Sven Ackermann, Anna-Katharin Theuser, Nadine Hummel, Sibylle Boehm, Rainer Kimmig, Alexander Reinthaller, Sven Becker, Felix Hilpert, Wolfgang Janni, Ignace Vergote, Phlipp Harter, Julius Emons, Alexander Hein, Matthias W. Beckmann, Peter A. Fasching, Patrik Pöschke, for the AGO Uterus Commission
Before the era of immunotherapies and antibody–drug conjugates, there were limited chemotherapeutic options for patients with recurrent and metastatic cervical cancer. Combination therapies with cisplatin have shown some superiority over monotherapy. This study examined platinum-free treatment regimens, comparing a combination of topotecan and paclitaxel (TP) with topotecan and cisplatin (TC) in patients
-
Corrigendum to “Self-reported lower extremity lymphedema and quality of life after surgical staging of endometrial carcinoma: A population based cross-sectional study” [Gynecologic Oncology 175 (2023) 72–80] Gynecol. Oncol. (IF 4.7) Pub Date : 2024-03-13 Pernille K. Bjerre Trent, Nina Jebens Nordskar, Knut R. Wangen, Ms. Ida Engeskaug, Ms. Linn Ø. Opheim, Guro Aune, Anne Cathrine Staff, Lene Thorsen, Ragnhild S. Falk, Ane Gerda Z. Eriksson
-
Impact of pharmacogenomic profiles on post-surgical pain following laparotomy for gynecologic pathology Gynecol. Oncol. (IF 4.7) Pub Date : 2024-03-12 Gretchen E. Glaser, Brandon Maddy, Amanika Kumar, Karen Ishitani, Maureen A. Lemens, Kristine Hanson, Ann M. Moyer, Elizabeth Habermann, Sean C. Dowdy
The aim of this prospective study was to compare perioperative opioid use in women by status of , a highly polymorphic pharmacogene relevant to opioid metabolism. Patients undergoing laparotomy were prospectively recruited and provided a preoperative saliva swab for a pharmacogenomic (PGx) gene panel. Postoperative opioid usage and pain scores were evaluated via chart review and a phone survey. Pharmacogenes
-
Integration and usability of a digital cancer risk stratification tool to optimize identification of patients at risk for hereditary cancers: A pilot study Gynecol. Oncol. (IF 4.7) Pub Date : 2024-03-08 Emily M. Webster, Luiza Perez, Muhammad Danyal Ahsan, Sarah Levi, Isabelle Chandler, Charlene Thomas, Kemi Babagbemi, Ravi N. Sharaf, Melissa K. Frey
Patients with a personal or family history of cancer may have elevated risk of developing future cancers, which often remains unrecognized due to lapses in screening. This pilot study assessed the usability and clinical outcomes of a cancer risk stratification tool in a gynecologic oncology clinic. New gynecologic oncology patients were prompted to complete a commercially developed personal and family
-
Mutations in cancer-relevant genes are ubiquitous in histologically normal endometrial tissue Gynecol. Oncol. (IF 4.7) Pub Date : 2024-03-06 Deep Pandya, Shannon Tomita, Maria Padron Rhenals, Sabina Swierczek, Katherine Reid, Olga Camacho-Vanegas, Catalina Camacho, Kelsey Engelman, Stephanie Polukort, Jordan RoseFigura, Linus Chuang, Vaagn Andikyan, Samantha Cohen, Paul Fiedler, Steven Sieber, Ie-Ming Shih, Jean-Noël Billaud, Robert Sebra, Boris Reva, Peter Dottino, John A. Martignetti
Endometrial cancer (EndoCA) is the most common gynecologic cancer and incidence and mortality rate continue to increase. Despite well-characterized knowledge of EndoCA-defining mutations, no effective diagnostic or screening tests exist. To lay the foundation for testing development, our study focused on defining the prevalence of somatic mutations present in non-cancerous uterine tissue. We obtained
-
2023 FIGO staging system for endometrial cancer: The evolution of the revolution Gynecol. Oncol. (IF 4.7) Pub Date : 2024-03-06 David Gaffney, Xavier Matias-Guiu, David Mutch, Giovanni Scambia, Carien Creutzberg, Christina Fotopoulou, Jonathan S. Berek, Nicole Concin
Embracing the complex and diverse nature of the heterogenous group of malignancies that are included under the umbrella of “endometrial cancer” (EC) to better align prognosis with treatment recommendations, requires a more comprehensive staging system. Our goal at the development of the new FIGO staging was to provide 1) high accuracy in the predictive prognosis for a patient with EC, which is the
-
Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer Gynecol. Oncol. (IF 4.7) Pub Date : 2024-03-05 Debra L. Richardson, Kathleen N. Moore, Ignace Vergote, Lucy Gilbert, Lainie P. Martin, Gina M. Mantia-Smaldone, Cesar M. Castro, Diane Provencher, Ursula A. Matulonis, James Stec, Yuemei Wang, Michael Method, David M. O'Malley
Evaluate the antitumor activity and safety profile of the triplet combination of mirvetuximab soravtansine (MIRV), carboplatin, and bevacizumab in recurrent, platinum-sensitive ovarian cancer. Participants with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancer (1–2 prior lines of therapy) received MIRV (6 mg/kg adjusted ideal body weight), carboplatin (AUC5)
-
Implementation of a surgical site infection prevention bundle in gynecologic oncology patients: An enhanced recovery after surgery initiative Gynecol. Oncol. (IF 4.7) Pub Date : 2024-03-01 Maede Ejaredar, Shannon M. Ruzycki, Tali Sara Glazer, Pat Trudeau, Brent Jim, Gregg Nelson, Anna Cameron
To evaluate the clinical outcomes pre- and post-implementation of an evidence-informed surgical site infection prevention bundle (SSIPB) in gynecologic oncology patients within an Enhanced Recovery After Surgery (ERAS) care pathway. Patients undergoing laparotomy for a gynecologic oncology surgery between January–June 2017 (pre-SSIPB) and between January 2018–December 2020 (post-SSIPB) were compared
-
A multi-center study to predict the risk of intraoperative hypothermia in gynecological surgery patients using preoperative variables Gynecol. Oncol. (IF 4.7) Pub Date : 2024-02-29 Bingbing Cao, Yongxing Li, Yongjian Liu, Xiangnan Chen, Yong Liu, Yao Li, Qiang Wu, Fengtao Ji, Haihua Shu
Hypothermia is highly common in patients undergoing gynecological surgeries under general anesthesia, so the length of hospitalization and even the risk of mortality are substantially increased. Our aim was to develop a simple and practical model to preoperatively identify gynecological surgery patients at risk of intraoperative hypothermia. In this retrospective study, we collected data from 802 patients
-
Diagnosis and management of gastric-type endocervical adenocarcinoma: A case report and review of the literature Gynecol. Oncol. (IF 4.7) Pub Date : 2024-02-29 Julia Chalif, Quinn Kistenfeger, Jessica Fulton, Molly Morton, Ivana DeVengencie, Wegahta Weldemichael, Jennifer Vazzano, David M. O'Malley, Laura M. Chambers
Gastric-type endocervical adenocarcinoma (GEA), a rare subtype of cervical cancer, has garnered increasing attention recently for its distinctive histopathological features, unique classification, genetic characteristics, and variable clinical outcomes compared to squamous cell and adenocarcinoma subtypes. Historically, GEA has evolved from a poorly understood entity to a distinct subtype of cervical
-
Laparoscopic predictability of minimally invasive interval debulking in advanced ovarian cancer: The MIID-SOC trial Gynecol. Oncol. (IF 4.7) Pub Date : 2024-02-27 Anthony B. Costales, Erin K. Crane, Laura Chambers, Meng Yao, Danielle Chau, Wendel R. Naumann, Robert Debernardo, Stephanie Ricci, Peter G. Rose, Chad M. Michener
We sought to create a laparoscopic-based model to predict the ability to perform a minimally invasive (MIS) cytoreductive surgery in advanced epithelial ovarian cancer patients who have received neoadjuvant chemotherapy (NACT). Fifty women were enrolled in a multi-institutional prospective pilot study . Each patient underwent laparoscopic evaluation of 43 abdominopelvic sites followed by surgeon dictated
-
The role of surgeon specialty in management and survival of malignant ovarian germ cell tumors: A population-based study Gynecol. Oncol. (IF 4.7) Pub Date : 2024-02-27 Lina Salman, Allan Covens, Danielle Vicus, Sho Podolsky, Ning Liu, Lilian T. Gien
The aim of this study is to describe management and survival in adult patients with malignant ovarian germ cell tumors (MOGCT) undergoing surgery by general gynecologists (GG) versus gynecologic oncologists (GO). This is a population-based retrospective cohort study, including patients (age ≥ 18 years old) with MOGCT identified in the provincial cancer registry of Ontario, (1996–2020). Baseline characteristics
-
Hidden in plain sight – Survival consequences of baseline symptom burden in women with recurrent ovarian cancer Gynecol. Oncol. (IF 4.7) Pub Date : 2024-02-26 Felicia Roncolato, Madeleine T. King, Rachel L. O'Connell, Yeh Chen Lee, Florence Joly, Felix Hilpert, Anne Lanceley, Yoshio Yoshida, Jane Bryce, Paul Donnellan, Amit Oza, Elisabeth Avall-Lundqvist, Jonathan S. Berek, Jonathan A. Ledermann, Dominique Berton, Jalid Sehouli, Marie-Christine Kaminsky, Martin R. Stockler, Michael Friedlander
To describe the baseline symptom burden(SB) experienced by patients(pts) with recurrent ovarian cancer(ROC) prior and associations with progression free survival (PFS) and overall survival (OS). We analysed baseline SB reported by pts. with platinum resistant/refractory ROC (PRR-ROC) or potentially‑platinum sensitive ROC receiving their third or greater line of chemotherapy (PPS-ROC≥3) enrolled in
-
Potential of molecular classification to guide fertility-sparing management among young patients with endometrial cancer Gynecol. Oncol. (IF 4.7) Pub Date : 2024-02-24 Nuria Agusti, Alexa Kanbergs, Roni Nitecki
The traditional histological classification system for endometrial carcinoma falls short in addressing the disease's molecular heterogeneity, prompting the need for alternative stratification methods. Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) has emerged as a clinically efficient tool to categorize endometrial cancers according to mismatch repair deficiency, POLE exonuclease
-
Risk of borderline ovarian tumors after fertility treatment - Results from a Danish cohort of infertile women Gynecol. Oncol. (IF 4.7) Pub Date : 2024-02-21 Anna Kjær Kristensen, Clarissa Lima Brown Frandsen, Bugge Nøhr, Jakob Hansen Viuff, Marie Hargreave, Kirsten Frederiksen, Susanne K. Kjær, Allan Jensen
-
A spatial proteomic study of platinum refractory HGSOC implicates dual AKT and WNT activity linked to an immunosuppressive tumor microenvironment Gynecol. Oncol. (IF 4.7) Pub Date : 2024-02-20 Carly B. Scalise, Kaitlyn Kincaid, Haley Thigpen, Jennah Moore, Bailee Dover, Lyse Norian, Selene Meza-Perez, Troy Randall, Michael Birrer, Kunle Odunsi, Rebecca C. Arend
Advanced-stage high-grade serous ovarian cancer (HGSOC) remains a deadly gynecologic malignancy with high rates of disease recurrence and limited, effective therapeutic options for patients. There is a significant need to better stratify HGSOC patients into platinum refractory (PRF) vs. sensitive (PS) cohorts at baseline to improve therapeutic responses and survival outcomes for PRF HGSOC. We performed
-
Incidence and risk factors of venous and arterial thromboembolic events among patients with ovarian cancer- data from a large Canadian database Gynecol. Oncol. (IF 4.7) Pub Date : 2024-02-20 Sydney Penfound, Alexandra Lukey, Jessica Hodgson, Wilma M. Hopman, Gillian E. Hanley, Maha Othman
-
Racial disparities in endometrial cancer: Where are we after 26 years? Gynecol. Oncol. (IF 4.7) Pub Date : 2024-02-20 Michael L. Hicks, Maya M. Hicks, Roland P. Mathews, Dineo Khabele, Camille A. Clare, Onyinye Balogun, Yolanda R. Lawson, Ronda Henry Tillman, Raleigh Butler, Cyril O. Spann, Groesbeck P. Parham
-
Determination of quality of life-related health utilities for surgical complications in ovarian cancer Gynecol. Oncol. (IF 4.7) Pub Date : 2024-02-19 Rudy S. Suidan, Charlotte C. Sun, Amy K. Schneider, Karen H. Lu, Sharon H. Giordano, Larissa A. Meyer
To assess the health state utilities of ovarian cancer patients, clinicians, and non-cancer controls regarding surgical complications in ovarian cancer. Utilities for 14 surgical complications were assessed from patients with recently diagnosed or recurrent ovarian cancer, clinicians, and non-cancer controls using the visual analog scale (VAS) and time trade-off (TTO) methods. Health state utilities
-
Robotic versus vaginal radical trachelectomy for reproductive-aged patients with early-stage cervical carcinoma: A multi-center cohort study Gynecol. Oncol. (IF 4.7) Pub Date : 2024-02-19 Andra Nica, Anouk Benseler, Ashna Parbhakar, Ly-Ann Teo Fortin, Marguerite Heyns, Marette Lee, Al Covens, Marie Plante, Taymaa May
A randomized non-inferiority trial showed worse survival in women with early-stage cervical cancer treated with radical hysterectomy by minimally invasive approach compared to laparotomy; the impact of surgical approach on survival following radical trachelectomy is unknown. To examine oncologic outcomes in women with early-stage cervical cancer who underwent robotic or vaginal radical trachelectomy
-
Prevalence of trauma history and symptoms in patients who have received vaginal brachytherapy as part of their endometrial cancer treatment Gynecol. Oncol. (IF 4.7) Pub Date : 2024-02-17 Anjali L. Saripalli, Dylan H. Ross, Elizabeth Murphy, Kayéromi Gomez, Sarah Thilges, Matthew M. Harkenrider
Vaginal brachytherapy (VBT) is an essential component of curative intent treatment for many patients with endometrial cancer. The prevalence of trauma history in this population is unknown and important to understand considering VBT requires patients to have an instrument vaginally inserted while in the vulnerable lithotomy position. We aim to identify patients treated with intracavitary VBT and collect
-
EGFL6 promotes endometrial cancer cell migration and proliferation Gynecol. Oncol. (IF 4.7) Pub Date : 2024-02-17 Alison A. Garrett, Shoumei Bai, Sandra Cascio, Navneet Gupta, Dongli Yang, Ronald J. Buckanovich
EGFL6, a growth factor produced by adipocytes, is upregulated in and implicated in the tumorigenesis of multiple tumor types. Given the strong link between obesity and endometrial cancer, we sought to determine the impact of EGFL6 on endometrial cancer. EGFL6 expression in endometrial cancer and correlation with patient outcomes was evaluated in the human protein atlas and TCGA. EGFL6 treatment, expression
-
Factors associated with loss to follow up after abnormal cervical cancer screening in pregnancy Gynecol. Oncol. (IF 4.7) Pub Date : 2024-02-17 Kelsey A. Roof, Hannah K. Wichmann, Laura J. Carlton, Minh L. Nguyen, George G. Birdsong, Danielle M. Blemur, Lisa C. Flowers
To assess risk factors associated with loss to follow up in patients referred for colposcopy after abnormal cervical cytology during pregnancy in a Southern safety net hospital population. An urban colposcopy center was queried for patients referred for follow up of abnormal cervical cytology during pregnancy and the postpartum period. Patients were identified through a standardized referral code in
-
Adenoid cystic carcinoma of the Bartholin's gland is underpinned by MYB- and MYBL1- rearrangements Gynecol. Oncol. (IF 4.7) Pub Date : 2024-02-17 Jacqueline Feinberg, Arnaud Da Cruz Paula, Edaise M. da Silva, Fresia Pareja, Juber Patel, Yingjie Zhu, Pier Selenica, Mario M. Leitao, Nadeem R. Abu-Rustum, Jorge S. Reis-Filho, Amy Joehlin-Price, Britta Weigelt
Adenoid cystic carcinoma (AdCC) of the Bartholin's gland (AdCC-BG) is a very rare gynecologic vulvar malignancy. AdCC-BGs are slow-growing but locally aggressive and are associated with high recurrence rates. Here we sought to characterize the molecular underpinning of AdCC-BGs. AdCC-BGs ( = 6) were subjected to a combination of RNA-sequencing, targeted DNA-sequencing, reverse-transcription PCR, fluorescence
-
The impact of body mass index on robotic surgery outcomes in endometrial cancer Gynecol. Oncol. (IF 4.7) Pub Date : 2024-02-17 Eva Kadoch, Yoav Brezinov, Gabriel Levin, Florentin Racovitan, Susie Lau, Shannon Salvador, Walter H. Gotlieb
To compare surgical outcomes of patients with endometrial cancer who underwent robotic surgery across different BMI categories. A retrospective study including all consecutive patients with endometrial cancer who underwent robotic surgery at a tertiary cancer center between December 2007 and December 2022. The study analyzed outcome measures, including blood loss, surgical times, length of hospitalization
-
The impact of Black founding fathers on the specialty of gynecologic oncology Gynecol. Oncol. (IF 4.7) Pub Date : 2024-02-16 Michael L. Hicks, Roland P. Matthews, Camille A. Clare, Yolanda R. Lawson, Dineo Khabele, Maya M. Hicks, Cyril O. Spann, Groesbeck P. Parham
The formative period of the specialty of gynecologic oncology was from 1968 to 1972 and became a board-certified specialty in 1973. During this formation there were no Black physicians participating in this process. We chronicle and document the incorporation of the first three board-certified Black physicians in the specialty of gynecologic oncology here for historical purposes. We highlight the hostile
-
Efficacy, safety, and feasibility of Apixaban for postoperative venous thromboembolism prophylaxis following open gynecologic cancer surgery at a comprehensive cancer center Gynecol. Oncol. (IF 4.7) Pub Date : 2024-02-16 Anne Knisely, Maria D. Iniesta, Samantha Batman, Larissa A. Meyer, Pamela T. Soliman, Katherine E. Cain, Claire Marten, Gary Chisholm, Kathleen M. Schmeler, Jolyn S. Taylor, Nicole D. Fleming
To evaluate safety, efficacy, and feasibility of apixaban for postoperative venous thromboembolism (VTE) prophylaxis following open gynecologic cancer surgery at a comprehensive cancer center. This retrospective, cohort study included patients with gynecologic cancer who underwent open surgery between 3/2021 and 3/2023 and received 28-day postoperative VTE prophylaxis. Patients on therapeutic anticoagulation
-
Impact of disease recurrence on the supportive care needs of patients with ovarian cancer and their caregivers Gynecol. Oncol. (IF 4.7) Pub Date : 2024-02-15 Tracey DiSipio, Gunter Hartel, Phyllis Butow, Penelope M. Webb, Vanessa L. Beesley
We aimed to explore the supportive care needs of ovarian cancer patients and their caregivers before and after the first cancer recurrence, the top unmet needs after recurrence, and the relationship between patient and caregiver needs at recurrence. Participants were 288 patients and 140 caregivers from the Australian Ovarian Cancer Study-Quality of Life (AOCS-QoL) cohort. They completed Supportive
-
Human epidermal growth factor receptor-2 (HER2) expression in FIGO3 high-grade endometrial endometrioid carcinoma: Clinicopathologic characteristics and future directions Gynecol. Oncol. (IF 4.7) Pub Date : 2024-02-15 Evi Abada, Seongho Kim, Hyejeong Jang, Mira Kheil, Kamaljeet Singh, Sudeshna Bandyopadhyay, Rouba Ali-Fehmi, M. Ruhul Quddus
To study the expression of HER2 in high-grade FIGO3 endometrial endometroid carcinoma (EEC) and to correlate our findings with the clinicopathologic characteristics of this tumor. HER2 expression by immunohistochemistry (IHC) was performed on 10% formalin-fixed paraffin embedded tissue on cases diagnosed as FIGO3 EEC. HER2 expression was interpreted as negative (0), low (1+ and 2+) or positive (3+)
-
-
-
What's in your “lunchbox”? Sandwich versus sequential chemotherapy and irradiation for advanced endometrial cancer Gynecol. Oncol. (IF 4.7) Pub Date : 2024-02-14 Gretchen Glaser, John Weroha
-
Survival disparities in non-Hispanic Black and White cervical cancer patients vary by histology and are largely explained by modifiable factors Gynecol. Oncol. (IF 4.7) Pub Date : 2024-02-10 Calen W. Kucera, Nicole P. Chappell, Chunqiao Tian, Michael T. Richardson, Christopher M. Tarney, Chad A. Hamilton, John K. Chan, Daniel S. Kapp, Charles A. Leath, Yovanni Casablanca, Christine Rojas, Collin A. Sitler, Lari Wenzel, Ann Klopp, Nathaniel L. Jones, Rodney P. Rocconi, John H. Farley, Timothy D. O'Connor, Craig D. Shriver, Nicholas W. Bateman, Thomas P. Conrads, Neil T. Phippen, G. Larry
We investigated racial disparities in survival by histology in cervical cancer and examined the factors contributing to these disparities. Non-Hispanic Black and non-Hispanic White (hereafter known as Black and White) patients with stage I-IV cervical carcinoma diagnosed between 2004 and 2017 in the National Cancer Database were studied. Survival differences were compared using Cox modeling to estimate
-
High grade adverse event reporting and enrolment in gynecologic oncology clinical trials Gynecol. Oncol. (IF 4.7) Pub Date : 2024-02-10 Ainhoa Madariaga, Heather Cole, Tyler Pittman, Robert C Grant, Neesha C Dhani, Amy Liu, Valerie Bowering, Susanna Sellman, Amit M. Oza, Stephanie Lheureux
The primary objective is to assess factors associated with treatment related high grade (CTCAE grade ≥ 3) adverse event (AE) reporting among participants in gynecologic oncology clinical trials. All AEs recorded in the Princess Margaret Clinical Trial adverse event database between 01/2016 and 12/2018 were evaluated. Gynecologic oncology clinical trials assessing systemic therapy were included. Inferential
-
High concordance of molecular subtyping between pre-surgical biopsy and surgical resection specimen (matched-pair analysis) in patients with vulvar squamous cell carcinoma using p16- and p53-immunostaining Gynecol. Oncol. (IF 4.7) Pub Date : 2024-02-10 Anne Kathrin Höhn, Mirjam Forberger, Mona Alfaraidi, C. Blake Gilks, Christine Elisabeth Brambs, Michael Höckel, Lynn Hoang, Naveena Singh, Lars-Christian Horn
Vulvar squamous cell carcinoma (VSCC) can be stratified into three molecular subtypes based on the immunoexpression of p16 and p53: HPV-independent p53-abnormal (p53abn) (most common, biologically aggressive), HPV-associated, with p16-overexpression (second most common, prognostically more favourable) and more recently recognised HPV-independent p53-wildtype (p53wt) (rarest subtype, prognostically
-
GPX3 supports ovarian cancer tumor progression in vivo and promotes expression of GDF15 Gynecol. Oncol. (IF 4.7) Pub Date : 2024-02-10 Caroline Chang, Ya-Yun Cheng, Shriya Kamlapurkar, Sierra White, Priscilla W. Tang, Amal T. Elhaw, Zaineb Javed, Katherine M. Aird, Karthikeyan Mythreye, Rébécca Phaëton, Nadine Hempel
We previously reported that high expression of the extracellular glutathione peroxidase GPX3 is associated with poor patient outcome in ovarian serous adenocarcinomas, and that GPX3 protects ovarian cancer cells from oxidative stress in culture. Here we tested if GPX3 is necessary for tumor establishment and to identify novel downstream mediators of GPX3's pro-tumorigenic function. GPX3 was knocked-down
-
Survival rates in Hispanic/Latinx subpopulations with cervical cancer associated with disparities in guideline-concordant care Gynecol. Oncol. (IF 4.7) Pub Date : 2024-02-09 Andreea I. Dinicu, Shayan Dioun, Yongzhe Wang, Yongmei Huang, Jason D. Wright, Ana I. Tergas
Failure to deliver guideline-concordant treatment may contribute to disparities among Hispanic/Latinx cervical cancer patients. This study investigated the association between survival rates in Hispanic/Latinx subpopulations and the provision of guideline-concordant care. We analyzed patients with primary cervical cancer from 2004 to 2019 (National Cancer Database). We developed nine quality metrics
-
Identifying safe diagnostic algorithms for sentinel lymph node mapping in high-risk endometrial cancer: The SENTIREC-endo study Gynecol. Oncol. (IF 4.7) Pub Date : 2024-02-09 Sarah Marie Bjørnholt, Ole Mogensen, Kirsten Bouchelouche, Sara Elizabeth Sponholtz, Erik Thorlund Parner, Malene Grubbe Hildebrandt, Annika Loft, Gudrun Neumann, Signe Frahm Bjørn, Katja Dahl, Algirdas Markauskas, Ligita Paskeviciute Frøding, Pernille Tine Jensen
It is unclear if sentinel node (SLN) mapping can replace pelvic- (PLD) and paraaortic lymphadenectomy (PALD) for high-risk endometrial cancer (EC). A diagnostically safe surgical algorithm, taking failed mapping cases into account, is not defined. We aimed to investigate the diagnostic accuracy of SLN mapping algorithms in women with exclusively high-risk EC. We undertook a prospective national diagnostic
-
Prognostic value of three-tiered scoring system for lymph-vascular space invasion in endometrial cancer: A systematic review and meta-analysis Gynecol. Oncol. (IF 4.7) Pub Date : 2024-02-09 Ling Han, Yali Chen, Ai Zheng, Xin Tan, Hengxi Chen
To investigate the impact of lymph-vascular space invasion (LVSI) status on the prognosis of endometrial cancer (EC) according to a three-tiered scoring system for LVSI. PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), International Clinical Trials Registry Platform (ICTRP), and Clinical were searched from inception to September 1st, 2023. The analysis was conducted using STATA
-
A comprehensive population-based study of malignant ovarian tumors, including histologic and immunohistochemical review, in children and adolescents 0–19 years old in Sweden between 1970 and 2014 Gynecol. Oncol. (IF 4.7) Pub Date : 2024-02-09 Sandra Wessman, Monica Nistér, Georgia Kokaraki, Niklas Pal, Giorgio Tettamanti, Tirzah Braz Petta, Joseph W. Carlson
Ovarian tumors in the pediatric population are rare. The incidence and frequency of subtypes differ between children and adults. Although not all tumors are aggressive, they may still lead to morbidity. The goal of this study was a comprehensive review of malignant ovarian tumors in children and adolescents diagnosed and registered in Sweden. Individuals were identified through a search in the National
-
A systematic review of ethnic minority participation in randomised controlled trials of systemic therapies for gynecological cancers Gynecol. Oncol. (IF 4.7) Pub Date : 2024-02-07 Luke Steventon, Shibani Nicum, Kenneth Man, Ubonphan Chaichana, Li Wei, Pinkie Chambers
Randomised controlled trials (RCTs) must include ethnic minority patients to produce generalisable findings and ensure health equity as cancer incidence rises globally. This systematic review examines participation of ethnic minorities in RCTs of licensed systemic anti-cancer therapies (SACT) for gynecological cancers, defining the research population and distribution of research sites to identify
-
Trends in ovarian, fallopian tube, and primary peritoneal cancer incidence, mortality, and survival: A 15-year population-based analysis Gynecol. Oncol. (IF 4.7) Pub Date : 2024-02-07 Sahana Somasegar, Ravali A. Reddy, Stephanie Chow, Oliver Dorigo, Malte Renz, Amer Karam
To characterize trends in ovarian, fallopian tube, and primary peritoneal cancer incidence and incidence-based mortality based on histology and site of origin. We obtained age-adjusted incidence and incidence-based mortality for patients with ovarian, fallopian tube, and primary peritoneal cancer from 2000 to 2019 from the US SEER 17 database. Joinpoint 4.9.1.0 was used to characterize log-linear time
-
Authentic leadership in action: Experience gained from a gynecologic oncology fellowship leadership curriculum Gynecol. Oncol. (IF 4.7) Pub Date : 2024-02-07 Monica D. Levine, Vincent M. Wagner, Courtney J. Riedinger, Wafa Khadraoui, Paulina J. Haight, Molly Morton, David E. Cohn
-
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial Gynecol. Oncol. (IF 4.7) Pub Date : 2024-02-06 Bhavana Pothuri, Sileny Han, Dana M. Chase, Florian Heitz, Robert A. Burger, Lydia Gaba, Linda Van Le, Eva Guerra, David Bender, Jacob Korach, Noelle Cloven, Cristina Churruca, Philippe Follana, Paul DiSilvestro, Jean-François Baurain, Kris Jardon, Carmela Pisano, Ulla Peen, Johanna Mäenpää, Divya Gupta, Emeline Bacqué, Yong Li, Natalie Compton, Jenya Antonova, Bradley J. Monk, Antonio González-Martín
To assess patient-reported health-related quality of life (HRQoL) in patients with ovarian cancer (OC) who received niraparib as first-line maintenance therapy. PRIMA/ENGOT-OV26/GOG-3012 (NCT02655016) enrolled patients with newly diagnosed advanced OC who responded to first-line platinum-based chemotherapy. Patients were randomized (2:1) to niraparib or placebo once daily in 28-day cycles until disease
-
Variation in telemedicine usage in gynecologic cancer: Are we widening or narrowing disparities? Gynecol. Oncol. (IF 4.7) Pub Date : 2024-02-05 Anna Jo Bodurtha Smith, Emily G. Gleason, Leslie Andriani, Jonathan Heintz, Emily M. Ko
Introduction Telemedicine rapidly increased with the COVID-19 pandemic and could reduce cancer care disparities. Our objective was to evaluate sociodemographic (race, insurance), patient, health system, and cancer factors associated with telemedicine use in gynecologic cancers. Methods We conducted a retrospective cohort study of patients with endometrial cancer and epithelial ovarian cancer with at
-
Impact of different follow-up regimens on health-related quality of life and costs in endometrial cancer patients: Results from the TOTEM randomized trial Gynecol. Oncol. (IF 4.7) Pub Date : 2024-02-03 Rosalba Rosato, Annamaria Ferrero, Paola Mosconi, Giovannino Ciccone, Daniela Di Cuonzo, Andrea Evangelista, Luca Fuso, Elisa Piovano, Eva Pagano, Maria Elena Laudani, Luca Pace, Paolo Zola
To investigate whether intensive follow-up (INT) after surgery for endometrial cancer impact health-related quality of life (HRQoL) and healthcare costs compared to minimalist follow-up (MIN), in the absence of evidence supporting any benefit on 5-year overall survival. In the TOTEM trial, HRQoL was assessed using the SF-12 and the Psychological General Well-Being (PGWB) questionnaires at baseline
-
2023 changes to FIGO endometrial cancer staging: Counterpoint Gynecol. Oncol. (IF 4.7) Pub Date : 2024-02-03 Mario M. Leitao
Abstract not available
-
Calendar-period trends in cervical precancer and cancer diagnoses since the introduction of human papillomavirus and cytology co-testing into routine cervical cancer screening at Kaiser Permanente Northern California Gynecol. Oncol. (IF 4.7) Pub Date : 2024-01-31 Brian Befano, Nicolas Wentzensen, Thomas Lorey, Nancy Poitras, Li C. Cheung, Mark Schiffman, Megan A. Clarke, Camryn Cohen, Walter Kinney, Alex Locke, Philip E. Castle
Objectives The longer-term impact of introducing human papillomavirus (HPV) testing into routine cervical cancer screening on precancer and cancer rates by histologic type has not been well described. Calendar trends in diagnoses were examined using data from Kaiser Permanente Northern California, which introduced triennial HPV and cytology co-testing in 2003 for women aged ≥30 years. Methods We examined
-
Variation in cervical cancer screening test utilization and results in a United States-based program Gynecol. Oncol. (IF 4.7) Pub Date : 2024-01-31 Vanessa G. Dorismond, Mona Saraiya, Sameer V. Gopalani, Ashwini Soman, Kristy Kenney, Jacqueline Miller, George F. Sawaya
Background Little is known about cervical cancer screening strategy utilization (cytology alone, cytology plus high-risk human papillomavirus [HPV] testing [cotesting], primary HPV testing) and test results in the United States. Methods Data from the Centers for Disease Control and Prevention's National Breast and Cervical Cancer Early Detection Program were analyzed for 199,578 persons aged 21–65 years
-
Molecular profiling of gestational trophoblastic neoplasia: Identifying therapeutic targets Gynecol. Oncol. (IF 4.7) Pub Date : 2024-01-31 Leah McNally, Sharon Wu, Kurt Hodges, Matt Oberley, John J. Wallbillich, Nathaniel L. Jones, Thomas J. Herzog, Premal H. Thaker, Angeles Alvarez Secord, Marilyn Huang
Objective The treatment for high risk or recurrent gestational trophoblastic neoplasia (GTN) is a highly toxic multi-agent chemotherapy. For patients with progressive or recurrent GTN, checkpoint inhibitors have demonstrated anti-tumor activity; however, identification of novel therapies for GTN remain an unmet need. Therefore, we sought to characterize the molecular landscape of GTN to identify potential
-
The emerging and challenging role of PD-L1 in patients with gynecological cancers: An updating review with clinico-pathological considerations Gynecol. Oncol. (IF 4.7) Pub Date : 2024-01-30 Angela Santoro, Giuseppe Angelico, Frediano Inzani, Damiano Arciuolo, Antonio d'Amati, Francesca Addante, Antonio Travaglino, Giulia Scaglione, Nicoletta D'Alessandris, Michele Valente, Giordana Tinnirello, Antonio Raffone, Nadine Narducci, Federica Cianfrini, Emma Bragantini, Gian Franco Zannoni
Over recent years, there has been significant progress in the development of immunotherapeutic molecules designed to block the PD-1/PD-L1 axis. These molecules have demonstrated their ability to enhance the immune response by prompting T cells to identify and suppress neoplastic cells. PD-L1 is a type 1 transmembrane protein ligand expressed on T lymphocytes, B lymphocytes, and antigen-presenting cells
-
Social determinants of health in uterine carcinosarcoma Gynecol. Oncol. (IF 4.7) Pub Date : 2024-02-02 Larissa L. Aroche Gutierrez, Donald D. McIntire, Jayanthi Lea, Salvatore LoCoco, David Scott Miller
UCS survival outcome disparities by race have been reported. We aimed to investigate social determinants of health (SDOH) and their relation to survival outcomes in women at two affiliated high-volume institutions serving a racially and economically diverse population. Women diagnosed with stage I-IV UCS treated at St. Paul University Hospital, University of Texas Southwestern (UTSW) Zale Lipshy Pavilion—William
-
Short-term survival analysis of a risk-adjusted model for ovarian cancer care Gynecol. Oncol. (IF 4.7) Pub Date : 2024-02-02 Anjali Hari, Jenny Chang, Carolina Villanueva, Argyrios Ziogas, Veronica Vieira, Robert E. Bristow
To quantify the impact on short-term ovarian cancer survival associated with treatment at high-performing hospitals using the observed-to-expected ratio (O/E) for adherence to ovarian cancer treatment guidelines as a risk-adjusted measure of hospital quality care. This was a retrospective population-based study of stage I-IV invasive epithelial ovarian cancer reported to California Cancer Registry
-
Evaluation of prognostic potential of β-catenin and L1CAM expression according to endometrial cancer risk group Gynecol. Oncol. (IF 4.7) Pub Date : 2024-02-02 Heesoo Yoon, Dong Hoon Suh, Kidong Kim, Jae Hong No, Yong Beom Kim, Hyojin Kim
We investigate the prognostic role of β-catenin and L1 neuronal cell-adhesion molecule (L1CAM) according to risk groups in endometrial carcinomas (EC). A total of 335 EC patients were classified according to the Proactive Molecular Risk Classifier for Endometrial Cancer. We evaluated the expression of ß-catenin and L1CAM using immunohistochemistry, and their association with clinicopathological characteristics
-
Rural-urban disparities in psychosocial functioning in epithelial ovarian cancer patients Gynecol. Oncol. (IF 4.7) Pub Date : 2024-02-02 Rachel Telles, M. Bridget Zimmerman, Premal H. Thaker, George M. Slavich, Edgardo S. Ramirez, Sharaf Zia, Michael J. Goodheart, Steven W. Cole, Anil K. Sood, Susan K. Lutgendorf
Although rural residence has been related to health disparities in cancer patients, little is known about how rural residence impacts mental health and quality of life (QOL) in ovarian cancer patients over time. This prospective longitudinal study investigated mental health and QOL of ovarian cancer patients in the first-year post-diagnosis. Women with suspected ovarian cancer completed psychosocial